Application of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research.
Mass spectrometry imaging is being increasingly used in metal-based anticancer drug development to study elemental and/or molecular drug distributions in different biological systems. The main analytical tools employed are SIMS (especially nanoSIMS), LA-ICP-MSI and MALDI-MSI as well as a combination of complementary imaging techniques. Main challenges are appropriate sample preparation methods, reliable and validated quantification strategies and a trade-off between sensitivity and spatial resolution. So far, research has mostly focused on the development of analytical methods for imaging with the long term goal to study drug uptake into tumor tissue and toxicity affected organs and to identify cellular targets of metal-based drugs. In this review we cover the technological features of the mass spectrometry imaging methods used and give an overview of the applications in metal-based anticancer drug research as well as some future perspectives.
Institute of Chemical Sciences and Engineering, École Polytechnique Fédérale de Lausanne (EPFL), CH1-1015 Lausanne, Switzerland. paul.dyson@epfl.ch.
Ronald F S
RFS
Lee
Sarah
S
Theiner
Anders
A
Meibom
Gunda
G
Koellensperger
Bernhard K
BK
Keppler
Paul J
PJ
Dyson
D000818:Animals; D000970:Antineoplastic Agents / Q000032:analysis* / Q000493:pharmacokinetics; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D008670:Metals / Q000032:analysis* / Q000493:pharmacokinetics; D009369:Neoplasms / Q000188:drug therapy; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods; D018629:Spectrometry, Mass, Secondary Ion / Q000379:methods
D000970:Antineoplastic Agents; D008670:Metals